CA2158173C - Methode pour le traitement de comportements de dependance - Google Patents

Methode pour le traitement de comportements de dependance Download PDF

Info

Publication number: CA2158173C
Authority: CA; Canada
Prior art keywords: agonist; serotonin; dopamine; behavior; pharmaceutical composition
Prior art date: 1993-03-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002158173A

Other languages

English (en)

Other versions

CA2158173A1 (fr

Inventor

Pietr Hitzig

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-17

Filing date

1994-03-17

Publication date

2001-12-04

1994-03-17 Application filed by Individual filed Critical Individual

1994-09-29 Publication of CA2158173A1 publication Critical patent/CA2158173A1/fr

2001-12-04 Application granted granted Critical

2001-12-04 Publication of CA2158173C publication Critical patent/CA2158173C/fr

2014-03-17 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000006399 behavior Effects 0.000 title claims abstract description 17
238000000034 method Methods 0.000 title description 4
239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 17
239000000952 serotonin receptor agonist Substances 0.000 claims abstract description 16
238000011282 treatment Methods 0.000 claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
235000020824 obesity Nutrition 0.000 claims abstract description 8
208000008589 Obesity Diseases 0.000 claims abstract description 7
208000028683 bipolar I disease Diseases 0.000 claims abstract description 5
230000007357 depressive behavior Effects 0.000 claims abstract 4
DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical group CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 20
DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims description 17
229960001582 fenfluramine Drugs 0.000 claims description 17
208000007848 Alcoholism Diseases 0.000 claims description 16
201000007930 alcohol dependence Diseases 0.000 claims description 12
229960003562 phentermine Drugs 0.000 claims description 10
239000002775 capsule Substances 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 41
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 38
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
229960003638 dopamine Drugs 0.000 description 20
239000003814 drug Substances 0.000 description 18
229940076279 serotonin Drugs 0.000 description 18
239000000203 mixture Substances 0.000 description 16
229940079593 drug Drugs 0.000 description 15
238000009472 formulation Methods 0.000 description 12
239000004480 active ingredient Substances 0.000 description 9
235000019788 craving Nutrition 0.000 description 8
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
230000007423 decrease Effects 0.000 description 6
229960002748 norepinephrine Drugs 0.000 description 6
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
230000001476 alcoholic effect Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
210000001009 nucleus accumben Anatomy 0.000 description 5
239000003826 tablet Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 4
230000035622 drinking Effects 0.000 description 4
229960002464 fluoxetine Drugs 0.000 description 4
238000002483 medication Methods 0.000 description 4
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000000556 agonist Substances 0.000 description 3
229940025084 amphetamine Drugs 0.000 description 3
210000004227 basal ganglia Anatomy 0.000 description 3
150000003943 catecholamines Chemical class 0.000 description 3
229960001653 citalopram Drugs 0.000 description 3
230000002354 daily effect Effects 0.000 description 3
230000003291 dopaminomimetic effect Effects 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
201000009032 substance abuse Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 2
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
102000010909 Monoamine Oxidase Human genes 0.000 description 2
108010062431 Monoamine oxidase Proteins 0.000 description 2
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229960003920 cocaine Drugs 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000003405 delayed action preparation Substances 0.000 description 2
229940052760 dopamine agonists Drugs 0.000 description 2
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
230000003382 ingestive effect Effects 0.000 description 2
230000002197 limbic effect Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
229960000299 mazindol Drugs 0.000 description 2
238000001690 micro-dialysis Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
238000000465 moulding Methods 0.000 description 2
229960002715 nicotine Drugs 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
229960002296 paroxetine Drugs 0.000 description 2
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
OJCPSBCUMRIPFL-UHFFFAOYSA-N prolintane Chemical compound C1CCCN1C(CCC)CC1=CC=CC=C1 OJCPSBCUMRIPFL-UHFFFAOYSA-N 0.000 description 2
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 2
238000009877 rendering Methods 0.000 description 2
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
230000000862 serotonergic effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000003461 thalamocortical effect Effects 0.000 description 2
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
238000004260 weight control Methods 0.000 description 2
DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
YAGBSNMZQKEFCO-SNVBAGLBSA-N (2r)-n-ethyl-1-phenylpropan-2-amine Chemical compound CCN[C@H](C)CC1=CC=CC=C1 YAGBSNMZQKEFCO-SNVBAGLBSA-N 0.000 description 1
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
MVXGSLGVWBVZCA-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]purine-2,6-dione;hydrochloride Chemical compound Cl.C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCNC(C)CC1=CC=CC=C1 MVXGSLGVWBVZCA-UHFFFAOYSA-N 0.000 description 1
QNJJECIHYZJXRL-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-methylpropan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)CC1=CC=CC=C1Cl QNJJECIHYZJXRL-UHFFFAOYSA-N 0.000 description 1
WEJDYJKJPUPMLH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-methylpropan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)CC1=CC=C(Cl)C=C1 WEJDYJKJPUPMLH-UHFFFAOYSA-N 0.000 description 1
VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 description 1
NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
IBWPUTAKVGZXRB-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)butan-2-ylhydrazine Chemical compound NNC(C)CCC1=CC=C2OCOC2=C1 IBWPUTAKVGZXRB-UHFFFAOYSA-N 0.000 description 1
MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
208000029197 Amphetamine-Related disease Diseases 0.000 description 1
206010071238 Binge Drinking Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 1
208000022497 Cocaine-Related disease Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
206010015535 Euphoric mood Diseases 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
206010056465 Food craving Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
206010049079 Labile hypertension Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
208000018526 Narcotic-Related disease Diseases 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
206010043087 Tachyphylaxis Diseases 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 1
FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960003225 alaproclate Drugs 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
229960000959 amineptine Drugs 0.000 description 1
ONNOFKFOZAJDHT-UHFFFAOYSA-N amineptine Chemical compound C1CC2=CC=CC=C2C(NCCCCCCC(=O)O)C2=CC=CC=C21 ONNOFKFOZAJDHT-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
229960002519 amoxapine Drugs 0.000 description 1
229940025141 anafranil Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
235000021407 appetite control Nutrition 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
229960000911 benserazide Drugs 0.000 description 1
YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
229960002837 benzphetamine Drugs 0.000 description 1
ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
-1 boluses Substances 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960001058 bupropion Drugs 0.000 description 1
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
229940015273 buspar Drugs 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
229960004301 butriptyline Drugs 0.000 description 1
ALELTFCQZDXAMQ-UHFFFAOYSA-N butriptyline Chemical compound C1CC2=CC=CC=C2C(CC(C)CN(C)C)C2=CC=CC=C21 ALELTFCQZDXAMQ-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229950007046 chlorphentermine Drugs 0.000 description 1
LQXYCDLHSKICDY-UHFFFAOYSA-N cianopramine Chemical compound C1CC2=CC=C(C#N)C=C2N(CCCN(C)C)C2=CC=CC=C21 LQXYCDLHSKICDY-UHFFFAOYSA-N 0.000 description 1
229950001408 cianopramine Drugs 0.000 description 1
229960002492 clobenzorex Drugs 0.000 description 1
LRXXRIXDSAEIOR-ZDUSSCGKSA-N clobenzorex Chemical compound C([C@H](C)NCC=1C(=CC=CC=1)Cl)C1=CC=CC=C1 LRXXRIXDSAEIOR-ZDUSSCGKSA-N 0.000 description 1
TZWKUQDQKPYNLL-UHFFFAOYSA-N cloforex Chemical compound CCOC(=O)NC(C)(C)CC1=CC=C(Cl)C=C1 TZWKUQDQKPYNLL-UHFFFAOYSA-N 0.000 description 1
229950008294 cloforex Drugs 0.000 description 1
229960004606 clomipramine Drugs 0.000 description 1
BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 1
HXCXASJHZQXCKK-UHFFFAOYSA-N clortermine Chemical compound CC(C)(N)CC1=CC=CC=C1Cl HXCXASJHZQXCKK-UHFFFAOYSA-N 0.000 description 1
229950000649 clortermine Drugs 0.000 description 1
XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 description 1
229950002663 clovoxamine Drugs 0.000 description 1
201000006145 cocaine dependence Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
231100000867 compulsive behavior Toxicity 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
229940099340 desoxyn Drugs 0.000 description 1
229960000632 dexamfetamine Drugs 0.000 description 1
229940099242 dexedrine Drugs 0.000 description 1
229960004597 dexfenfluramine Drugs 0.000 description 1
229960003075 dibenzepin Drugs 0.000 description 1
ZJDCGVDEEHWEIG-UHFFFAOYSA-N diclofensine Chemical compound C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 ZJDCGVDEEHWEIG-UHFFFAOYSA-N 0.000 description 1
229950007329 diclofensine Drugs 0.000 description 1
229940120144 didrex Drugs 0.000 description 1
229960004890 diethylpropion Drugs 0.000 description 1
XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
229960003524 dimetacrine Drugs 0.000 description 1
RYQOGSFEJBUZBX-UHFFFAOYSA-N dimetacrine Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 RYQOGSFEJBUZBX-UHFFFAOYSA-N 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229960001393 dosulepin Drugs 0.000 description 1
229960005426 doxepin Drugs 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
235000005686 eating Nutrition 0.000 description 1
229940011681 elavil Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960001003 etilamfetamine Drugs 0.000 description 1
230000002743 euphoric effect Effects 0.000 description 1
230000001552 evening effect Effects 0.000 description 1
OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
229950003930 femoxetine Drugs 0.000 description 1
BAQKJENAVQLANS-UHFFFAOYSA-N fenbutrazate Chemical compound C=1C=CC=CC=1C(CC)C(=O)OCCN(C1C)CCOC1C1=CC=CC=C1 BAQKJENAVQLANS-UHFFFAOYSA-N 0.000 description 1
229960002533 fenbutrazate Drugs 0.000 description 1
229940032465 fenethylline Drugs 0.000 description 1
229960001877 fenfluramine hydrochloride Drugs 0.000 description 1
IQUFSXIQAFPIMR-UHFFFAOYSA-N fenproporex Chemical compound N#CCCNC(C)CC1=CC=CC=C1 IQUFSXIQAFPIMR-UHFFFAOYSA-N 0.000 description 1
229960005231 fenproporex Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
230000005802 health problem Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
230000001127 hyperphagic effect Effects 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229960002844 iprindole Drugs 0.000 description 1
PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
229960002589 iproclozide Drugs 0.000 description 1
GGECDTUJZOXAAR-UHFFFAOYSA-N iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 description 1
229940070023 iproniazide Drugs 0.000 description 1
229960002672 isocarboxazid Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
JKAHWGPTNVUTNB-IXPVHAAZSA-N lergotrile Chemical compound C1=CC([C@H]2C[C@@H](CC#N)CN([C@@H]2C2)C)=C3C2=C(Cl)NC3=C1 JKAHWGPTNVUTNB-IXPVHAAZSA-N 0.000 description 1
229950007886 lergotrile Drugs 0.000 description 1
229960003587 lisuride Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
229960002813 lofepramine Drugs 0.000 description 1
SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
230000007774 longterm Effects 0.000 description 1
ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
229940110127 marplan Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 description 1
229950006217 mebanazine Drugs 0.000 description 1
210000004245 medial forebrain bundle Anatomy 0.000 description 1
229960001468 mefenorex Drugs 0.000 description 1
XXVROGAVTTXONC-UHFFFAOYSA-N mefenorex Chemical compound ClCCCNC(C)CC1=CC=CC=C1 XXVROGAVTTXONC-UHFFFAOYSA-N 0.000 description 1
229960004794 melitracen Drugs 0.000 description 1
GWWLWDURRGNSRS-UHFFFAOYSA-N melitracen Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 GWWLWDURRGNSRS-UHFFFAOYSA-N 0.000 description 1
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229950008693 mesulergine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960004650 metergoline Drugs 0.000 description 1
WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
229960001252 methamphetamine Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
229960004758 minaprine Drugs 0.000 description 1
LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 1
229960004644 moclobemide Drugs 0.000 description 1
YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
229940087524 nardil Drugs 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229960003057 nialamide Drugs 0.000 description 1
229940087480 norpramin Drugs 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
GPTURHKXTUDRPC-UHFFFAOYSA-N noxiptiline Chemical compound C1CC2=CC=CC=C2C(=NOCCN(C)C)C2=CC=CC=C21 GPTURHKXTUDRPC-UHFFFAOYSA-N 0.000 description 1
229950004461 noxiptiline Drugs 0.000 description 1
201000005040 opiate dependence Diseases 0.000 description 1
229960005290 opipramol Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940053544 other antidepressants in atc Drugs 0.000 description 1
229960002888 oxitriptan Drugs 0.000 description 1
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
229940055692 pamelor Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940000596 parlodel Drugs 0.000 description 1
229940087824 parnate Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229960000761 pemoline Drugs 0.000 description 1
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
229960004851 pergolide Drugs 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
229940088507 permax Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
229960000436 phendimetrazine Drugs 0.000 description 1
229960000964 phenelzine Drugs 0.000 description 1
OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
229960003209 phenmetrazine Drugs 0.000 description 1
229960001277 phentermine hydrochloride Drugs 0.000 description 1
229960004310 piribedil Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
229960004654 prolintane Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
YFLBETLXDPBWTD-UHFFFAOYSA-N propizepine Chemical compound O=C1N(CC(C)N(C)C)C2=CC=CC=C2NC2=NC=CC=C21 YFLBETLXDPBWTD-UHFFFAOYSA-N 0.000 description 1
229950003857 propizepine Drugs 0.000 description 1
JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
229960000786 propylhexedrine Drugs 0.000 description 1
229960002601 protriptyline Drugs 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
229960000279 quinupramine Drugs 0.000 description 1
JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229940099204 ritalin Drugs 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
235000019553 satiation Nutrition 0.000 description 1
238000007789 sealing Methods 0.000 description 1
229960003946 selegiline Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
229940001089 sinemet Drugs 0.000 description 1
235000015096 spirit Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
229940118176 surmontil Drugs 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
229940034887 tenuate Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
HNONSDNCRNUTCT-UHFFFAOYSA-N tiflorex Chemical compound CCNC(C)CC1=CC=CC(SC(F)(F)F)=C1 HNONSDNCRNUTCT-UHFFFAOYSA-N 0.000 description 1
229950005141 tiflorex Drugs 0.000 description 1
229940041597 tofranil Drugs 0.000 description 1
229960002309 toloxatone Drugs 0.000 description 1
PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
229960003741 tranylcypromine Drugs 0.000 description 1
229960003991 trazodone Drugs 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
229960001255 viloxazine Drugs 0.000 description 1
229940045977 vivactil Drugs 0.000 description 1
235000013522 vodka Nutrition 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
229940020965 zoloft Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002158173A 1993-03-17 1994-03-17 Methode pour le traitement de comportements de dependance Expired - Fee Related CA2158173C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3483493A	1993-03-17	1993-03-17
US08/034,834		1993-03-17
PCT/US1994/002875 WO1994021244A1 (fr)	1993-03-17	1994-03-17	Procede de traitement de comportements de dependance

Publications (2)

Publication Number	Publication Date
CA2158173A1 CA2158173A1 (fr)	1994-09-29
CA2158173C true CA2158173C (fr)	2001-12-04

Family

ID=21878899

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002158173A Expired - Fee Related CA2158173C (fr)	1993-03-17	1994-03-17	Methode pour le traitement de comportements de dependance

Country Status (4)

Country	Link
EP (1)	EP0710106A4 (fr)
AU (1)	AU6410394A (fr)
CA (1)	CA2158173C (fr)
WO (1)	WO1994021244A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4467396A (en)	1994-12-12	1996-07-10	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain, inflammation and spasm
US6413961B1 (en)	1995-12-12	2002-07-02	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain and inflammation
FR2760190B1 (fr) *	1997-02-28	1999-04-09	Adir	Composition pharmaceutique pour la liberation programmee de dexfenfluramine
DK1426049T3 (da)	2002-12-02	2005-08-22	Sanol Arznei Schwarz Gmbh	Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10334188B4 (de)	2003-07-26	2007-07-05	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung von Depressionen
WO2009091605A2 (fr) *	2008-01-17	2009-07-23	Health Innovations, Llc	Traitements de titration du goût
KR102385359B1 (ko)	2010-11-08	2022-04-11	오메로스 코포레이션	Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en)	2010-11-08	2015-12-29	Omeros Corporation	Treatment of addiction and impulse-control disorders using PDE7 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4255439A (en) *	1979-07-13	1981-03-10	Irving Cooper	Means and method for aiding individuals to stop smoking

1994
- 1994-03-17 CA CA002158173A patent/CA2158173C/fr not_active Expired - Fee Related
- 1994-03-17 EP EP94911627A patent/EP0710106A4/fr not_active Withdrawn
- 1994-03-17 WO PCT/US1994/002875 patent/WO1994021244A1/fr not_active Ceased
- 1994-03-17 AU AU64103/94A patent/AU6410394A/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0710106A4 (fr)	1999-07-21
CA2158173A1 (fr)	1994-09-29
AU6410394A (en)	1994-10-11
WO1994021244A1 (fr)	1994-09-29
EP0710106A1 (fr)	1996-05-08

Legal Events

Date	Code	Title	Description
1998-01-27	EEER	Examination request
2009-03-17	MKLA	Lapsed

Publication	Publication Date	Title
US5502080A (en)	1996-03-26	Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5776969A (en)	1998-07-07	Treatment of sleep disorders
US6169105B1 (en)	2001-01-02	Potentiation of drug response
US5658955A (en)	1997-08-19	Combined use of dopamine and serotonin agonists in the treatment of immune disorders
US5532250A (en)	1996-07-02	Potentiation of drug response
AU2006323048B2 (en)	2013-07-04	Compositions and methods for increasing insulin sensitivity
US20020187958A1 (en)	2002-12-12	Treatment of pain
US20040077730A1 (en)	2004-04-22	Medical treatment
JPH02501065A (ja)	1990-04-12	肥満、うつ病、薬物の乱用およびナルコレプシーの処置方法および組成物
CA2318920A1 (fr)	1999-08-05	Utilisations pharmaceutiques de (-)-bupropion optiquement pur
WO2005065308A2 (fr)	2005-07-21	Compositions et procedes permettant de traiter des etats pathologiques recurrents
TWI325320B (en)	2010-06-01	Active ingredient combination for pharmacological addictive substance or intoxicant therapy
EP0759299B1 (fr)	2000-04-26	Potentialisation de la sérotonine
EP0792649A1 (fr)	1997-09-03	Traitement de l'insomnie
EP0386117B1 (fr)	1999-01-07	Traitement du syndrome de phase luteale tardive ou premenstruelle
KR101408650B1 (ko)	2014-06-20	무스카린성 수용체 ｍ1 길항제를 이용한 심리 질환 치료 방법
EP0710106A1 (fr)	1996-05-08	Procede de traitement de comportements de dependance
Kennedy et al.	1991	Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa
Roe	1997	From DOPA to Parkinson's disease: the early history of dopamine research
EP4175643A1 (fr)	2023-05-10	Compositions et procédés pour traiter des troubles psychiatriques ou des symptômes de ceux-ci
US6335372B1 (en)	2002-01-01	Treatment of obsessive compulsive disorder
CA2338326A1 (fr)	2000-02-10	Procedes et compositions pour le traitement et la prevention des toxicomanies a l'aide de moclobemide
EP1667686A1 (fr)	2006-06-14	Association d'inhibiteurs de recaptage de la serotonine et d'inhibiteurs de recaptage de la noradrenaline
Galloway et al.	1996	A historically controlled trial of tyrosine for cocaine dependence
EP1631276A2 (fr)	2006-03-08	Compositions destinees a un traitement renforce de la depression